Authors: Loh KP, Christofyllakis K, Huang LW, Mims A
Journal of materials chemistry. B
Authors: Tsai CC, Hong YJ, Lee RJ, Cheng NC, Yu J
PloS one
Authors: Adedimeji A, Sinayobye JD, Asiimwe-Kateera B, Chaudhry J, Buzinge L, Gitembagara A, Murenzi G, Mugenzi P, Patel VV, Castle PE, Mutesa L, Palefsky J, Anastos KM
Annals of surgery
Authors: Haugen CE, McAdams-DeMarco M, Holscher CM, Ying H, Gurakar AO, Garonzik-Wang J, Cameron AM, Segev DL, Lai JC
Gastroenterology
Authors: Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND
Journal of the National Cancer Institute
Authors: Nollen NL, Mayo MS, Cox LS, Benowitz NL, Tyndale RF, Ellerbeck EF, Scheuermann TS, Ahluwalia JS
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
Authors: Hanna DB, Lazar JM, Avadhani S, Kaplan RC, Anastos K, Gange SJ, Holman S, Minkoff HL, Kizer JR
Volume 94 of Issue 1 | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
Authors: Faggioni M, Baber U, Chandrasekhar J, Sartori S, Weintraub W, Rao SV, Vogel B, Claessen B, Kini A, Effron M, Ge Z, Keller S, Strauss C, Snyder C, Toma C, Weiss S, Aquino M, Baker B, Defranco A, Bansilal S, Muhlestein B, Kapadia S, Pocock S, Poddar KL, Henry TD, Mehran R
OBJECTIVE
To investigate the use of prasugrel after percutaneous coronary intervention (PCI) in African American (AA) patients presenting with acute coronary syndrome (ACS).
BACKGROUND
AA patients are at higher risk for adverse cardiovascular outcomes after PCI and may derive greater benefit from the use of potent antiplatelet therapy.
METHODS
Using the multicenter PROMETHEUS observational registry of ACS patients treated with PCI, we grouped patients by self-reported AA or other races. Clinical outcomes at 90-day and 1-year included non-fatal myocardial infarction (MI), major adverse cardiac events (composite of death, MI, stroke, or unplanned revascularization) and major bleeding.
RESULTS
The study population included 2,125 (11%) AA and 17,707 (89%) non-AA patients. AA patients were younger, more often female (46% vs. 30%) with a higher prevalence of diabetes mellitus, chronic kidney disease, and prior coronary intervention than non-AA patients. Although AA patients more often presented with troponin (+) ACS, prasugrel use was much less common in AA vs. non-AA (11.9% vs. 21.4%, respectively, P = 0.001). In addition, the use of prasugrel increased with the severity of presentation in non-AA but not in AA patients. Multivariable logistic regression showed AA race was an independent predictor of reduced use of prasugrel (0.42 [0.37-0.49], P < 0.0001). AA race was independently associated with a significantly higher risk of MI at 90-days and 1 year after PCI.
CONCLUSIONS
Despite higher risk clinical presentation and worse 1-year ischemic outcomes, AA race was an independent predictor of lower prasugrel prescription in a contemporary population of ACS patients undergoing PCI.
View on PubMed
Scientific Reports
Authors: Menon M, Elliott R, Bowers L, Balan N, Rafiq R, Costa-Cabral S, Munkonge F, Trinidade I, Porter R, Campbell AD, Johnson ER, Esdar C, Buchstaller HP, Leuthner B, Rohdich F, Schneider R, Sansom O, Wienke D, Ashworth A, Lord CJ
Cellular and molecular gastroenterology and hepatology
Authors: Tse CM, Yin J, Singh V, Sarker R, Lin R, Verkman AS, Turner JR, Donowitz M
